Real-world impact and effectiveness of MenACWY-TT-Reference-Cited by-同舟云学术

Real-world impact and effectiveness of MenACWY-TT

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Villena Rodolfo¹²,Kriz Paula³,Tin Tin Htar Myint⁴,Burman Cindy⁵,Findlow Jamie⁶,Balmer Paul⁵,Jodar Luis⁵

Affiliation:

1. Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile

2. Infectious Diseases Unit, Hospital de niños Dr. Exequiel González Cortés, Santiago, Chile

3. Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic

4. Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Paris, France

5. Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

6. Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Ltd, Tadworth, UK

Funder

ponsored by Pfizer Inc

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2251825

Reference48 articles.

1. Global epidemiology of invasive meningococcal disease

2. Global epidemiology of meningococcal disease

3. History of meningococcal vaccines and their serological correlates of protection

4. WHO. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [accessed 2022 Jan 27]. https://apps.who.int/immunization_monitoring/globalsummary/schedules.

5. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

2. Facilitating the development of urgently required combination vaccines;The Lancet Global Health;2024-06